Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion type Assertion NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_head.
- NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_provenance.
- NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion evidence source_evidence_literature NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_provenance.
- NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion SIO_000772 15543614 NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_provenance.
- NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion wasDerivedFrom befree-2016 NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_provenance.
- NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion wasGeneratedBy ECO_0000203 NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_provenance.